MXPA04003234A - Formas de dosificacion de particlas multiples de propanonol de liberacion sostenida, programada. - Google Patents

Formas de dosificacion de particlas multiples de propanonol de liberacion sostenida, programada.

Info

Publication number
MXPA04003234A
MXPA04003234A MXPA04003234A MXPA04003234A MXPA04003234A MX PA04003234 A MXPA04003234 A MX PA04003234A MX PA04003234 A MXPA04003234 A MX PA04003234A MX PA04003234 A MXPA04003234 A MX PA04003234A MX PA04003234 A MXPA04003234 A MX PA04003234A
Authority
MX
Mexico
Prior art keywords
propranolol
sustained release
pharmaco
timed
dosage forms
Prior art date
Application number
MXPA04003234A
Other languages
English (en)
Inventor
S Vishnupad Krishna
Original Assignee
Eurand Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Pharmaceuticals Ltd filed Critical Eurand Pharmaceuticals Ltd
Publication of MXPA04003234A publication Critical patent/MXPA04003234A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

Una forma de dosificacion unitaria, tal como una capsula o similar para administrar farmacos dentro del cuerpo en una modalidad de liberacion circadiana, comprende una o mas poblaciones de particulas que contienen propranolol (perlas, pellets, granulos, etc.). Cada poblacion de granulos exhibe un perfil de liberacion sostenida o rapida previamente disenado con o sin un lapso de tiempo previamente determinado de 3 a 5 horas. Dicho sistema de administracion cardiovascular de liberacion de acuerdo al ritmo circadiano, esta disenado para proporcionar un perfil de tiempo-concentracion, que varia de acuerdo con una necesidad fisiologica durante el dia, por ejemplo, imitando el ritmo circadiano y la manifestacion de severidad de una enfermedad cardiovascular, pronosticada en base a consideraciones farmaco-cineticas y farmaco-dinamicas y en correlaciones in vitro/in vivo.
MXPA04003234A 2001-10-04 2002-10-02 Formas de dosificacion de particlas multiples de propanonol de liberacion sostenida, programada. MXPA04003234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/971,167 US6500454B1 (en) 2001-10-04 2001-10-04 Timed, sustained release systems for propranolol
PCT/US2002/031535 WO2003028708A1 (en) 2001-10-04 2002-10-02 Timed, sustained release multi-particulate dosage forms of propranolol

Publications (1)

Publication Number Publication Date
MXPA04003234A true MXPA04003234A (es) 2004-08-12

Family

ID=25518009

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003234A MXPA04003234A (es) 2001-10-04 2002-10-02 Formas de dosificacion de particlas multiples de propanonol de liberacion sostenida, programada.

Country Status (12)

Country Link
US (2) US6500454B1 (es)
EP (1) EP1432411B1 (es)
JP (1) JP4369752B2 (es)
KR (1) KR101090719B1 (es)
AT (1) ATE442134T1 (es)
AU (1) AU2002330211B2 (es)
CA (1) CA2462637C (es)
DE (1) DE60233668D1 (es)
ES (1) ES2333306T3 (es)
MX (1) MXPA04003234A (es)
NO (1) NO335070B1 (es)
WO (1) WO2003028708A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7967756B2 (en) * 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Respiratory therapy control based on cardiac cycle
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
EP1722758A1 (en) * 2004-02-11 2006-11-22 Athpharma Limited Chronotherapeutic compositions and methods of their use
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006039491A1 (en) * 2004-10-01 2006-04-13 Reliant Pharmaceuticals, Inc. Treating morning migraines with propanolol
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060099258A1 (en) * 2004-11-05 2006-05-11 Grant Heinicke Propranolol formulations
US20060099259A1 (en) * 2004-11-05 2006-05-11 Grant Heinicke Propranolol formulations
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
AU2013273835B2 (en) * 2005-05-02 2016-07-07 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
DK1915137T3 (da) 2005-08-10 2013-11-04 Add Advanced Drug Delivery Technologies Ltd Oralt præparat med kontrolleret frisætning
ES2531215T3 (es) * 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
EP1976492B8 (en) * 2006-01-27 2018-07-04 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US8865210B2 (en) * 2006-02-13 2014-10-21 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
BRPI0711221A2 (pt) * 2006-05-26 2012-03-13 Auspex Pharmaceuticals, Inc Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
PL2222300T3 (pl) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny
MX2010006520A (es) * 2007-12-13 2010-11-30 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
JP5878022B2 (ja) * 2009-02-23 2016-03-08 アデア ファーマスーティカルズ，インコーポレイテッド 抗コリン薬を具える放出制御組成物
EP2506835B1 (en) 2009-11-30 2019-06-12 Adare Pharmaceuticals, Inc. Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CA2819663C (en) 2010-12-02 2019-12-24 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
WO2015004617A1 (en) * 2013-07-09 2015-01-15 Ranbaxy Laboratories Limited Extended-release pharmaceutical compositions of metoprolol
CN105287394A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸普萘洛尔缓释微丸及其制备方法
WO2019046251A1 (en) 2017-08-28 2019-03-07 Adare Pharmaceuticals, Inc. TIZANIDINE FORMULATIONS
JP2019052115A (ja) * 2017-09-15 2019-04-04 国立研究開発法人理化学研究所 医薬組成物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48A (en) * 1836-10-11 Turnout fob
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4851229A (en) 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
IE58401B1 (en) 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5376384A (en) 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6162463A (en) 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6039979A (en) 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol

Also Published As

Publication number Publication date
US20030157173A1 (en) 2003-08-21
JP4369752B2 (ja) 2009-11-25
AU2002330211B2 (en) 2007-02-01
WO2003028708A1 (en) 2003-04-10
CA2462637A1 (en) 2003-04-10
EP1432411B1 (en) 2009-09-09
KR101090719B1 (ko) 2011-12-08
NO335070B1 (no) 2014-09-01
EP1432411A1 (en) 2004-06-30
DE60233668D1 (de) 2009-10-22
US6500454B1 (en) 2002-12-31
ATE442134T1 (de) 2009-09-15
CA2462637C (en) 2010-12-07
NO20041740L (no) 2004-04-28
KR20040084890A (ko) 2004-10-06
ES2333306T3 (es) 2010-02-19
JP2005508922A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
MXPA04003234A (es) Formas de dosificacion de particlas multiples de propanonol de liberacion sostenida, programada.
HK1039569A1 (en) Timed pulsatile drug delivery systems.
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
CO4290295A1 (es) Medicamento en forma de comprimido con liberacion retardada de sustancia activa
BRPI0311701B8 (pt) formulação farmacêutica de dosagem multiparticulada revestida com liberação controlada de lamotrigina
IL131713A0 (en) Dosage forms comprising separate portions of r-and s-enantiomers
AU2003295614A8 (en) Delivery of pharmaceutical agents via the human insulin receptor
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
WO2007090091A3 (en) Drug delivery systems comprising weakly basic drugs and organic acids
DE60334775D1 (de) Mehrstufiges orales arzneimittelsystem mit kontrollierter freisetzung
AP1659A (en) Orally administered controlled drug delivery system providing temporal and spatial control.
HK1091725A1 (en) Aripiprazole injectable suspension
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2006030431A3 (en) Biocompatible drug delivery apparatus and methods
MXPA05012810A (es) Formas de dosis oral de memantina.
DE60212475D1 (de) Pharmazeutische Tablette und eine Verfahren zu deren Herstellung
HUP0500097A3 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
DK1171111T3 (da) Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning
WO2003099214A3 (en) Biguanide formulations
EP1578464A4 (en) THERAPEUTIC SINGLE DOSE GAS ADMINISTRATION SYSTEM
TW200500085A (en) Sustained-release pharmaceutical composition for lung administration
ZA200406881B (en) Medicaments containing betamimetic drugs and a novel anticholineterase drug
WO2003082342A1 (fr) Utilisation du gene k1aa0172 pour le traitement et le diagnostic de maladies et decouverte de medicaments
Wakelee-Lynch Interferon may offer first drug therapy for diabetic retinopathy. New research showing that alpha-interferon blocks new blood vessel formation in the iris of monkeys may point the way to new treatment for diabetes retinopathy
NO326141B1 (no) Fremgangsmate for behandling av isolert systolisk hypertensjon

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status